Goldman Sachs
DMRA

Goldman Sachs’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Goldman Sachs’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Buy
+88,336
New +$2.27M ﹤0.01% 4423
2021
Q2 		– Sell
-536
Closed -$81K – 6324
2021
Q1 		$81K Buy
+536
New +$146K ﹤0.01% 5880

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

Goldman Sachs's DMRA Position: Q1 2026 in Review

Goldman Sachs opened a new position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2026: 88,336 shares worth $2.29M. The stake represents ﹤0.01% of the portfolio and ranks #4423 among its holdings. This is a return to the name: Goldman Sachs previously reported a position in DMRA as recently as Q1 2021.

Goldman Sachs first reported a position in DMRA in Q1 2021 and has held it in 2 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • Goldman Sachs held 88,336 shares of Damora Therapeutics, Inc. Ordinary Shares worth $2.29M as of Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares was a new Goldman Sachs position in Q1 2026.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4423 holding.
  • Goldman Sachs first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q1 2021 and has held it in 2 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.